Pharmaceuticals

Short-Acting B2 Agonists Market to Grow at a CAGR of 4.1% from 2025 to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Short-Acting B2 Agonists Market Size During 2025–2029?

The short-acting B2 agonist market has experienced consistent growth in recent years. Projections indicate a rise from $4.25 billion in 2024 to $4.4 billion by 2025, reflecting a compound annual growth rate (CAGR) of 3.4%. Historically, this expansion is linked to an increase in the pediatric asthma population, a greater occurrence of environmental allergens, elevated urbanization and pollution levels, an increased emphasis on preventing asthma exacerbations, and a rise in research and development activities.

The market size for short-acting B2 agonists is anticipated to demonstrate consistent growth over the coming years, projected to reach “$5.18 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.1%. This expansion during the forecast period is largely attributed to the increasing prevalence of asthma and chronic obstructive pulmonary disease, enhanced awareness concerning asthma management, a rise in government initiatives for asthma and COPD treatment, increasing global healthcare expenditure, and the expanding geriatric population. Significant trends expected during this period include advancements in inhaler technologies, a growing market for personalized asthma treatments, the development of convenient drug delivery systems, technological improvements in nebulizers for home use, and refinements in drug formulations for improved efficacy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp

Which Drivers Are Impacting The Short-Acting B2 Agonists Market?

The anticipated rise in chronic obstructive pulmonary disease (COPD) cases is projected to drive expansion within the short-acting B2 agonists market in the future. COPD is a persistent respiratory condition characterized by impaired airflow and breathing challenges, primarily resulting from extended contact with detrimental gases or tobacco smoke. This increase in COPD can be attributed to heightened exposure to air pollution, since continuous inhalation of contaminants such as particulate matter and noxious gases can damage lung tissue and expedite the progression of the illness. Short-acting β2-agonists (SABAs) are employed in COPD to rapidly alleviate symptoms such as dyspnea by relaxing muscles in the airways. These serve as emergency treatments during acute exacerbations rather than for ongoing management. For example, data released in July 2024 by the Australian Institute of Health and Welfare, an Australia-based government body, indicated that in 2022, COPD was responsible for 7,691 deaths, equating to 29.6 per 100,000 population, which constituted 4.0% of all fatalities. Consequently, the growing incidence of chronic obstructive pulmonary disease is expected to stimulate the expansion of the short-acting B2 agonists market.

What Are The Segment Types Shaping The Short-Acting B2 Agonists Market?

The short-acting b2 agonists market covered in this report is segmented –

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Trends Are Redefining The Short-Acting B2 Agonists Market Dynamics?

Leading companies within the short-acting B2 agonists market are prioritizing the development of sophisticated products, like pressurized metered-dose inhalers (pMDI), to ensure efficient management of acute symptoms. Pressurized metered-dose inhalers (pMDIs) are portable devices designed to deliver a specific medication dose into the lungs in aerosol form, utilizing a propellant-driven spray, and are commonly employed for respiratory conditions such as asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-headquartered pharmaceutical and biotechnology company, disclosed the US Food and Drug Administration (FDA) approval of Airsupra (albuterol/budesonide). Airsupra represents a novel pressurized metered-dose inhaler (pMDI) that combines two active components in a single fixed-dose formulation. It incorporates albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to alleviate inflammation. This specific combination has been sanctioned in the US for the as-needed management and prevention of bronchoconstriction in adults suffering from asthma. Additionally, it contributes to reducing the likelihood of exacerbations, thereby offering a comprehensive approach to asthma care.

Which Leading Players Are Enhancing Their Short-Acting B2 Agonists Market Presence Worldwide?

Major companies operating in the short-acting B2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report

What Regional Growth Trends Are Shaping The Short-Acting B2 Agonists Market Outlook?

North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in the short-acting B2 agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Short-Acting B2 Agonists Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24396&type=smp

Browse Through More Reports Similar to the Global Short-Acting B2 Agonists Market 2025, By The Business Research Company

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795